Radiance
GHK-CU
100mg
$63.75$85.00
The Collection
Front
✦Third-party tested✦American made✦Ships in 24–48h
Radiance
GLOW
$101.25$135.00
Strength · 70mg
GLOW Blend 70mg lyophilized vial — 50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500. For in-vitro research into ECM remodeling and angiogenesis.
1
- Bulk
- 5+ vials — 5% · 10+ vials — 10% preferred rate
- Shipping
- Complimentary US shipping over $200
- Payment
- Card · Zelle · Venmo · Cash App
✦
✦
✦
Research Notice
For laboratory research use only. Not for human consumption.
The Dossier
Research Notes
GLOW is a co-lyophilized research blend that assembles three complementary tissue-remodeling references into a single vial: GHK-Cu (copper tripeptide-1), BPC-157, and TB-500. Its copper-tripeptide-dominant composition gives the powder a characteristic pale-blue tint.
It is studied for the combined signaling characteristics of its constituents in comparative models, consolidating three gold-standard references into one acquisition for laboratory convenience.
Research Focus
- ✦Dermal wound-healing and re-epithelialization models
- ✦Tendon, ligament, and skeletal-muscle repair models
- ✦Angiogenesis (ischemia) models
- ✦Dermatology and hair-follicle research
- ✦Anti-inflammatory and antioxidant models
Mechanism
The three components engage distinct, non-overlapping repair axes: GHK-Cu as a copper-delivery vehicle and broad gene modulator of extracellular-matrix synthesis; BPC-157 through VEGFR2-associated angiogenic signaling; and TB-500 through actin sequestration and cytoskeletal remodeling.
Convergent axes characterized across the single-agent literature include Nrf2/Keap1 antioxidant signaling and NF-κB modulation.
Storage & Handling
Store the lyophilized blend at −20°C for long-term stability. Reconstituted solution is held cold and used within a short window; avoid chelating agents, which can strip copper from the GHK-Cu component.
References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in light of new gene data. Int J Mol Sci. 2018.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation. J Mol Med. 2017.
✦Every vial ships with third-party HPLC verification; certificates of analysis are available on request.
Continue Exploring
